After Texas A&M's Pro Day on Thursday, here is what HC Mike Elko and three Aggies had to say after Thursday's event.

"Lakers in 5" is Shannon Sharpe's most well-known catchphrase at the moment, and it's recently started a bunch of memes on ...

The following clips were recorded by Marvel Rivals Esports from the live footage of the tournament. They highlight the best plays of Marvel Rivals Invitational 2025: North America Swiss Stage. In ...

NEW YORK, March 13, 2025 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company developing innovative gamma-delta T cell therapies, today reported financial ...

Shane joins Snake Saturday Publicist Mindy Hart in North Kansas City to chat about all the details of this year's Snake Saturday. Paul Craig with Theatre Tech Productions joins Shane in North ...

2024 and outlined recent business highlights. "2024 was an important year of execution as it relates to our clinical development programs in cardiovascular inflammation and thyroid eye disease,” said ...

The strong deal flow highlights continued momentum in the ... CRC-IB Managing Director. “Our recent deals demonstrate our ability to structure and negotiate complex transactions, helping clients ...

Despite concerns over tariffs and inflation, Miller appears undervalued and is recommended as a buy after its recent decline. Miller Industries has not been this cheap since Covid-19, and appears ...

and key corporate highlights. “We are coming off a tremendously successful year. Our 2024 total revenue nearly achieved blockbuster status, and we are just now building out our many ...

Louis Vuitton opened its fall/winter 2025 show with the sound of ... as its starting point for all things aesthetically, the latest showing came as no surprise. Models wound through the runway ...

Although the 27-year-old Moore doesn’t have extensive experience as a starter, there are highlights of his work. Here is Moore working against two-time Pro Bowl defensive end Brian Burns.

Shares in Novo Nordisk fell on Monday on a second set of worse than expected trial results for the latest obesity drug from the manufacturer of blockbuster treatments Ozempic and Wegovy.